drugset / Trial / NCT04162353
BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
Phase 1
Recruiting
12 enrolled
iCell Gene Therapeutics
Peking University Shenzhen Hospital · collabiCAR Bio Therapeutics Ltd. · collab
NaSequentialOpen-labelTreatment
Summary
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR in patients with relapsed and/or refractory multiple myeloma and plasmacytoid lymphoma.
Timeline
- Start
- 2019-07-01
- Primary completion
- 2026-07
- Completion
- 2026-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCMA-CD19 cCAR T cells | Cell therapy | 2e+06 cells/kg | Intravenous |
| Subject | BCMA-CD19 cCAR T cells | Cell therapy | 1e+07 cells/kg | Intravenous |